{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:09:55Z","timestamp":1760234995023,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sharyl and Oscar Garza Fund","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Michael Kriegel Foundation","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Sounder Foundation","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"NeOnc Technologies","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Departmental Funds","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which typically includes cytarabine (AraC), either alone or in combination with anthracyclines, but drug resistance can develop and significantly worsen prognosis. Better treatments are needed. We are developing a novel anticancer compound, NEO212, that was created by covalent conjugation of two different molecules with already established anticancer activity, the alkylating agent temozolomide (TMZ) and the natural monoterpene perillyl alcohol (POH). We investigated the anticancer activity of NEO212 in several in vitro and in vivo models of AML. Human HL60 and U937 AML cell lines, as well as different AraC-resistant AML cell lines, were treated with NEO212 and effects on cell proliferation, cell cycle, and cell death were investigated. Mice with implanted AraC-sensitive or AraC-resistant AML cells were dosed with oral NEO212, and animal survival was monitored. Our in vitro experiments show that treatment of cells with NEO212 results in growth inhibition via potent G2 arrest, which is followed by apoptotic cell death. Intriguingly, NEO212 was equally potent in highly AraC-resistant cells. In vivo, NEO212 treatment strikingly extended survival of AML mice and the majority of treated mice continued to thrive and survive without any signs of illness. At the same time, we were unable to detect toxic side effects of NEO212 treatment. All in all, the absence of side effects, combined with striking therapeutic activity even in an AraC-resistant context, suggests that NEO212 should be developed further toward clinical testing.<\/jats:p>","DOI":"10.3390\/cancers13143385","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:36:44Z","timestamp":1625571404000},"page":"3385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-5653","authenticated-orcid":false,"given":"Axel H.","family":"Sch\u00f6nthal","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Swenson","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu O.","family":"Minea","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Na","family":"Kim","sequence":"additional","affiliation":[{"name":"Department Pediatrics, Division of Hematology, Oncology, Blood and Bone Marrow Transplantation, Children\u2019s Hospital of Los Angeles, Los Angeles, CA 90027, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heeyeon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-7744","authenticated-orcid":false,"given":"Nazleen","family":"Mohseni","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Mi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department Pediatrics, Division of Hematology, Oncology, Blood and Bone Marrow Transplantation, Children\u2019s Hospital of Los Angeles, Los Angeles, CA 90027, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-4667","authenticated-orcid":false,"given":"Thomas C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/JEP.S254334","article-title":"Molecular targeting and rational chemotherapy in acute myeloid leukemia","volume":"12","author":"Pourrajab","year":"2020","journal-title":"J. Exp. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-13-0882","article-title":"A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo","volume":"13","author":"Chen","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2014.12.021","article-title":"A novel temozolomide analog, neo212, with enhanced activity against mgmt-positive melanoma in vitro and in vivo","volume":"358","author":"Chen","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2015.11.040","article-title":"A novel drug conjugate, neo212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells","volume":"371","author":"Jhaveri","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11912-019-0783-5","article-title":"Evidence-based practice: Temozolomide beyond glioblastoma","volume":"21","author":"Chua","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2002.01.030","article-title":"Phase i study of temozolomide in relapsed\/refractory acute leukemia","volume":"20","author":"Seiter","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","article-title":"A phase 1 study of the parp inhibitor veliparib in combination with temozolomide in acute myeloid leukemia","volume":"23","author":"Gojo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-8722-2-21","article-title":"Temozolomide and cisplatin in relapsed\/refractory acute leukemia","volume":"2","author":"Seiter","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00280-018-3731-4","article-title":"Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias","volume":"83","author":"Singh","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"key":"ref_11","first-page":"444","article-title":"Temozolomide-related hematologic toxicity","volume":"36","author":"Scaringi","year":"2013","journal-title":"Onkologie"},{"key":"ref_12","unstructured":"Wildman, R.E.C. (2001). Isoprenoids, health and disease. Neutraceuticals and Functional Foods, CRC Press."},{"key":"ref_13","first-page":"1580","article-title":"Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy","volume":"5","author":"Chen","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nthal, A.H., Peereboom, D.M., Wagle, N., Lai, R., Mathew, A.J., Hurth, K.M., Simmon, V.F., Howard, S.P., Taylor, L.P., and Chow, F. (2021). Phase i trial of intranasal neo100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neuro-Oncol. Adv., 3.","DOI":"10.1093\/noajnl\/vdab005"},{"key":"ref_15","first-page":"5625","article-title":"Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation","volume":"33","author":"Teixeira","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chen, T.C., Da Fonseca, C.O., and Sch\u00f6nthal, A.H. (2016). Perillyl alcohol and its drug-conjugated derivatives as potential novel methods of treating brain metastases. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17091463"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Minea, R.O., Duc, T.C., Swenson, S.D., Cho, H.Y., Huang, M., Hartman, H., Hofman, F.M., Schonthal, A.H., and Chen, T.C. (2020). Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238238"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/OTT.S191621","article-title":"Mechanisms of drug resistance in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco-Targets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36199","DOI":"10.1038\/srep36199","article-title":"Using genome-wide crispr library screening with library resistant dck to find new sources of ara-c drug resistance in aml","volume":"6","author":"Kurata","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Silva-Hirschberg, C., Hartman, H., Stack, S., Swenson, S., Minea, R.O., Davitz, M.A., Chen, T.C., and Sch\u00f6nthal, A.H. (2019). Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, neo212, on cutaneous t-cell lymphoma in vitro. Ther. Adv. Med. Oncol., 11.","DOI":"10.1177\/1758835919891567"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mrd.22489","article-title":"The imagej ecosystem: An open platform for biomedical image analysis","volume":"82","author":"Schindelin","year":"2015","journal-title":"Mol. Reprod. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","article-title":"Men and mice: Relating their ages","volume":"152","author":"Dutta","year":"2016","journal-title":"Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: Mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clml.2019.12.007","article-title":"Treatment strategies for therapy-related acute myeloid leukemia","volume":"20","author":"Dhakal","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/ctrv.2000.0186","article-title":"Treatment-related leukaemia\u2014A clinical and scientific challenge","volume":"26","author":"Ng","year":"2000","journal-title":"Cancer Treat. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/neuonc\/not036","article-title":"Secondary hematological malignancies associated with temozolomide in patients with glioma","volume":"15","author":"Momota","year":"2013","journal-title":"Neuro Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/ccr3.978","article-title":"Complete response to temozolomide in chronic lymphocytic leukemia","volume":"5","author":"Rao","year":"2017","journal-title":"Clin. Case Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/14\/3385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:26:38Z","timestamp":1760163998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/14\/3385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":28,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13143385"],"URL":"https:\/\/doi.org\/10.3390\/cancers13143385","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}